We plan to out-license our entire novel drugs pipeline: Glenmark CMD

We plan to out-license our entire novel drugs pipeline: Glenmark CMD Glenmark CMD Glenn Saldanha shares his vision of how he plans to grow the business in a challenging environment Mumbai: Indian pharmaceutical companies are on the cusp of a transformation from being generic drug makers to creating a pipeline of complex generics, speciality and innovative products through enhanced focus on research and development (R&D). Glenmark Pharmaceuticals Ltd’s growth strategy also revolves around making this transition. In fact, it is among the few Indian firms that started investing in new drug development way back in the year 2000. But unlike Read More


Glenmark Unveils its Strategic Blueprint for Transition Into an Innovation-led Global Pharmaceutical Organization in the Next Decade

Glenmark Unveils its Strategic Blueprint for Transition Into an Innovation-led Global Pharmaceutical Organization in the Next Decade – Leverages Company’s Industry-leading Capabilities to Expand Discovery and Development of Glenmark’s Robust Generics and Innovative Portfolio – Focuses Resources on Growth Catalysts – Focus on innovative new molecular entities (NME) – Filing as many as nine new drug application (NDA)/biologic license application (BLAs) in the next 10 years – Targeting 30 percent of total revenues from specialty and innovation segments over the next decade Glenmark Pharmaceuticals Ltd. (GPL), a global research-driven, integrated pharmaceutical company headquartered at Mumbai, today announced its ‘Strategic Blueprint Read More


Generic Pharma Companies Stand To Gain If Obamacare Repealed: Glenmark

Generic Pharma Companies Stand To Gain If Obamacare Repealed: Glenmark Glenmark Pharmaceuticals Ltd. says generic pharmaceutical companies would get a greater share of the American drug market, if the incoming Republican administration led by U.S. President-Elect Donald Trump were to repeal the Affordable Care Act – popularly known as Obamacare. Glemark unveiled a ten-year strategy plan on Monday, and said oncology, respiratory and dermatology will be key growth areas, going forward. The Mumbai-based pharma company plans to target at least 30 percent of its revenue from the speciality and innovation segment over the next decade. Spends on research and development Read More


Glenmark: steering financial deleverage through new products

Glenmark: steering financial deleverage through new products Glenmark sales, aided by strong growth in the US, increased by a healthy 16.5% but net profit grew just 3.5% and missed analysts’ estimates The Glenmark Pharmaceuticals Ltd stock has been falling steadily in the past few days. The company’s September quarter results have not been anything to write home about. Aided by strong growth in the US, sales increased by a healthy 16.5% but net profit grew just 3.5% and missed analysts’ estimates as high expenses and finance costs crimped earnings. Nevertheless, there are two factors aiding the stock. One is the Read More


Glenmark rises armed with research after five year hiatus

Glenmark rises armed with research after five year hiatus It’s been a while since Glenmark Pharmaceuticals licensed a drug. Between 2004 and 2011, arguably its best years in research, Glenmark cut as many as seven deals with multinational companies for indigenously developed drugs, which brought in $220 million in payments. Since then, there’s been a lull. The company’s last experimental drug was licensed to Paris headquartered Sanofi in a deal that would have garnered more than $600 million – a record. However, none of these drugs could be developed to secure regulatory approval. Glenmark’s push into innovation — seen as Read More


India’s Top 10 Powerful Influential Pharma Leaders 2016 List

India’s Top 10 Powerful Influential Pharma Leaders 2016 List India’s Top 10 Powerful Influential Pharma Leaders 2016 List Pricing, Regulatory Hurdles & OTC Market remain the key focus at Pharma Leaders 2016 Research Report. Dilip Shanghvi, Pankaj Patel, Samprada Singh, R.C.Juneja, Dilip Surana are among top 10 Powerful Indian Pharma Leaders 2016 Indian Pharmaceutical Industry has evolved as a dominant & powerful sector since india’s seventy years of independence & yet the industry remains largely fragmented with top 100 players in complete command of dominance. Today these top 100 companies have more than 80 % of the market share out Read More


Out-licensing yes, but with a more ‘mature’ approach, says Glenn Saldanha

Out-licensing yes, but with a more ‘mature’ approach, says Glenn Saldanha Glenn Saldanha does not believe that Glenmark has fallen silent on the licensing front. The next 12 to 18 months will see the company venture into out-licensing pacts with global partners to develop prospective drugs from the Glenmark stable, says Saldanha, Chairman and Managing Director. Only this time, the pacts will be approached with more “maturity”, as opposed to “doing deals for the next big cheque,” he says, reflecting on the company’s evolving strategy. “It’s more a timing issue. We’ve not slowed down in terms of work ….it’s just Read More


Glenn Saldanha of Glenmark Vice-President of Indian Pharmaceutical Alliance (IPA)

Nilesh Gupta of Lupin new president of IPA; Glenn Saldanha of Glenmark vice-president Nilesh Gupta, managing director of Lupin Limited, has taken over as president of the Indian Pharmaceutical Alliance (IPA) for 2015-17. Glenn Saldanha, chairman & managing director of Glenmark Pharmaceuticals Limited, is the new vice president. The IPA, initially formed by eight national companies in November 1999 has now 20 research based national pharmaceutical companies in its fold. Its current members are Dr Reddy’s Laboratories, Sun Pharmaceuticals Industries, Lupin, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Cadila Healthcare, Alkem Laboratories, Alembic, Mylan Labs, Micro Labs, Cadila Pharmaceuticals, Natco Pharma, Cipla, Panacea Read More


Mr. Glenn Saldanha Chairman & and Managing Director, Glenmark Pharmaceuticals Limited, conferred ‘India Pharma Leader Award’ by the Government of India

Mr. Glenn Saldanha Chairman & and Managing Director, Glenmark Pharmaceuticals Limited, conferred ‘India Pharma Leader Award’ by the Government of India As per reports, Union Minister for Chemicals and Fertilizers Ananth Kumar conferred 1st India Pharma awards in Bengaluru on Thursday evening. Speaking on the occasion, Ananth Kumar said that the Pharma Industry in the country is growing at a higher rate than GDP and needs to be complimented for this. “Indian government would like domestic Pharma industry to be global leaders,” he said, adding that the government and the Pharma entrepreneurs will work together as team Pharma India, with Read More


Glenmark expects big growth from US: Glenn Saldanha

Glenmark expects big growth from US: Glenn Saldanha Glenmark Pharmaceuticals posted 48 per cent growth in net profit in the third quarter of FY16, but the result disappointed the Street, which was expecting more robust sales and profit growth. In an email interview with Aneesh Phadnis, the company’s chairperson, Glenn Saldanha, explains the reasons behind the poor performance. Edited excerpts: The third quarter result was disappointing as it came below Street estimates on both sales and profit figures. What went wrong? In major markets, on a constant currency basis, we have recorded a topline growth of 15-20 per cent. The Read More


ˆ Back To Top